Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026)
Incannex Healthcare's (IXHL) quarterly Income from Continuing Operations came in at -$3.9 million in Q1 2026, up 2.14% year-over-year from -$3.8 million in Q1 2025, and up 40.45% quarter-over-quarter from -$6.5 million in Q4 2025.
Analysis
Incannex Healthcare (IXHL) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Incannex Healthcare has disclosed Income from Continuing Operations across 5 years of filings, most recently posting -$3.9 million for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 2.14% year-over-year to -$3.9 million; the TTM figure through Mar 2026 stood at -$48.4 million (down 122.97% YoY), while the FY2025 annual figure was -$46.9 million, down 154.0% from the prior year.
- Income from Continuing Operations came in at -$3.9 million for Q1 2026 at Incannex Healthcare, up from -$6.5 million in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of -$726000.0 in Q3 2023 to a low of -$31.6 million in Q2 2025.
- Average Income from Continuing Operations over 5 years is -$6.6 million, with a median of -$5.3 million recorded in 2023.
- Year-over-year, Income from Continuing Operations sank 646.56% in 2024 and soared 34.21% in 2025.
- Over 5 years, Income from Continuing Operations stood at -$2.9 million in 2022, then plunged by 79.61% to -$5.2 million in 2023, then fell by 12.46% to -$5.9 million in 2024, then decreased by 10.64% to -$6.5 million in 2025, then soared by 40.45% to -$3.9 million in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were -$3.9 million in Q1 2026, -$6.5 million in Q4 2025, and -$6.4 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.50 Bn | 622.74 Bn | 17.26 Bn | 5.53 Bn |
| 2 | AbbVie | 440.29 Bn | 433.72 Bn | 12.70 Bn | 3.62 Bn |
| 3 | Merck | 364.93 Bn | 357.79 Bn | 12.21 Bn | -1.34 Bn |
| 4 | Novartis Ag | 266.65 Bn | 258.96 Bn | 11.24 Bn | 5.28 Bn |
| 5 | Pfizer | 158.92 Bn | 147.22 Bn | 10.94 Bn | -246.00 Mn |
| 6 | Sanofi | 52.46 Bn | 45.08 Bn | 10.79 Bn | 2.16 Bn |
| 7 | Revolution Medicines | 44.32 Bn | 44.32 Bn | - | -644.37 Mn |
| 8 | Incyte | 25.32 Bn | 20.78 Bn | 1.57 Bn | 585.61 Mn |
| 9 | United Therapeutics | 21.42 Bn | 18.75 Bn | 683.80 Mn | 333.00 Mn |
| 10 | Incannex Healthcare | 41.43 Mn | 41.43 Mn | - | -3.88 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -3.88 Mn |
| Dec 31, 2025 | -6.52 Mn |
| Sep 30, 2025 | -6.41 Mn |
| Jun 30, 2025 | -31.60 Mn |
| Mar 31, 2025 | -3.97 Mn |
| Dec 31, 2024 | -5.89 Mn |
| Sep 30, 2024 | -5.42 Mn |
| Jun 30, 2024 | -6.43 Mn |
| Mar 31, 2024 | -6.03 Mn |
| Dec 31, 2023 | -5.24 Mn |
| Sep 30, 2023 | -726,000.00 |
| Jun 30, 2023 | -4.17 Mn |
| Mar 31, 2023 | -3.57 Mn |
| Dec 31, 2022 | -2.92 Mn |